Tag Datopotamab Deruxtecan

Clinical Trials, News

Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in BEGONIA Phase 1b/2 trial.

Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus Imfinzi (durvalumab) (Arm 7) showed that the combination demonstrated durable tumour responses and no new safety signals in patients with previously…

October 22, 2023

Clinical Trials, News

Positive topline results from the TROPION-Breast01 Phase 3 trial.

Positive topline results from the TROPION-Breast01 Phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progressionfree survival (PFS) compared to investigator’s choice of chemotherapy in patients with inoperable or…

September 22, 2023